Brief: Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity Of Icovamenib In Combination With Semaglutide In Type 2 Diabetes (T2d) Animal Model At The 61St Easd Annual Meeting And Provides Additional Corporate Update
16/09/2025 14:02
Sept 16 (Reuters) - Biomea Fusion Inc BMEA.O: BIOMEA FUSION PRESENTS DATA DEMONSTRATING ENHANCED PRECLINICAL ACTIVITY OF ICOVAMENIB IN COMBINATION WITH SEMAGLUTIDE IN TYPE 2 DIABETES (T2D) ANIMAL MODEL AT THE 61ST EASD ANNUAL MEETING AND PROVIDES ADDITIONAL CORPORATE UPDATE BIOMEA FUSION INC - PHASE I TRIAL FOR BMF-650 IN OBESITY ON TRACK WITH 28-DAY WEIGHT LOSS DATA EXPECTED IN HY 2026 Source text: ID:nGNXbKN2Q5 Further company coverage: BMEA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes